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Human T-cell lymphotropic virus type I (HTLV-I)-infected T-cell clones enter the S-phase of the cell cycle in the absence
of exogenous IL-2. The pathway by which HTLV-I activates the host T cell may circumvent normal immunoregulatory
mechanisms and thus be important for the pathogenesis of HTLV-I-induced diseases. The early control of viral infections is
in part mediated by interferons (IFNs), which possess both antiviral and antiproliferative functions. In order to investigate the
antiproliferative effect of IFN-b on HTLV-I-induced T-cell activation, we generated T-cell clones from patients with HTLV-I-
associated myelopathy/tropical spastic paraparesis by single-cell cloning under limiting dilution conditions. Here we
demonstrate that HTLV-I-induced T-cell proliferation is resistant to the antiproliferative action of IFN-b. Moreover, HTLV-I-
infected T-cell clones continue to constitutively secrete IFN-g in the presence of high doses of IFN-b. HTLV-I-infected T cells
express normal levels of IFNAR1 and are able to respond to IFN-b by phosphorylation of STAT1 on Tyr701, although they
display a relative increase in phosphorylation of the transcriptionally inactive STAT1b when compared with STAT1a. Thus,
HTLV-I promotes cell cycle progression in G1 by a mechanism that overcomes inhibitory signals, thereby circumventing an
innate immune defense mechanism. © 1999 Academic Pressc 1
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Human T-cell lymphotropic virus type I (HTLV-I) infects
mmune T cells and may cause disease by its ability to
nappropriately activate the immune system (Franchini,
995; Ho¨llsberg, 1997). Although the vast majority of
TLV-I-infected individuals remain asymptomatic, a lym-
hoproliferative or a chronic inflammatory disease may
evelop in a few percent of infected individuals
Franchini, 1995). In HTLV-I-associated myelopathy/trop-
cal spastic paraparesis (HAM/TSP), a chronic inflamma-
ory and demyelinating disease of the central nervous
ystem, approximately 10% of T cells harbor the virus
Ho¨llsberg et al., 1992; Richardson et al., 1990, 1997;
ucherpfennig et al., 1992). Although the HTLV-I infec-
ion of T cells is usually silent, with no detectable viral
ranscription (Richardson et al., 1997), the presence of
ntiviral IgM antibodies in HAM/TSP patients (Nagasato
t al., 1991) indicates active viral transcription in vivo.
his may give rise to the high viral load observed in
hese patients (Gessain et al., 1990) and secondarily may
rovoke a chronic stimulation of the immune system
anifested by a remarkably high frequency of viral-spe-
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ressed at Department of Medical Microbiology and Immunology, Bar-
holin Building, Aarhus University, DK-8000 Aarhus C, Denmark. Fax: 45
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314ific CD8 T cells (Bieganowska et al., 1999; Elovaara et
l., 1993; Greten et al., 1998).
In addition to the specific immune response, nonspe-
ific immunomodulating proteins control a viral infection.
s part of the innate immune response, interferons
IFNs) are induced by virus-infected cells and exert an
ntiviral and antiproliferative effect, which may help to
imit the expansion of the infection. IFNs are divided into
ype I and type II, and although type II IFN has antiviral
ctivity, it is type I IFNs that constitute the major antiviral
esponse (Hwang et al., 1995; Mu¨ller et al., 1994). Three
lasses of type I IFNs have been described, named a, v,
nd b, all of which mediate their action through the type
IFN receptor. The IFN type I receptor is composed of at
east two chains, IFNAR1 and IFNAR2, which are ex-
ressed on nearly all human cells. Null mutation of the
ene encoding IFNAR1 results in loss of both the antivi-
al and the antiproliferative responses to IFN-a and
FN-b (Hwang et al., 1995; Mu¨ller et al., 1994), indicating
n essential functional role of this receptor chain.
Upon ligand binding, IFNAR1 is tyrosine phosphory-
ated and the protein tyrosine kinases Tyk2 and JAK1
ecome activated (Abramovich et al., 1994; Beadling et
l., 1994; Platanias et al., 1994). This results in the recruit-
ent and phosphorylation of the signal transducer and
ctivator of transcription (STAT)1 on Tyr701 (Shuai et al.,
993). In their activated state, STAT1 proteins form ho-
odimers or heterodimers with STAT2 (Darnell, 1997), a
rotein that is constitutively associated with the IFNAR1
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315HTLV-I-INFECTED T CELLS EVADE ACTION OF IFN-bAbramovich et al., 1994). The STAT dimers translocate to
he nucleus and influence transcriptional activation (Dar-
ell, 1997). STAT1 transmits a critical and nonredundant
ntiviral signal, since mice deficient in STAT1 are com-
romised in their innate immune response to viral infec-
ions (Durbin et al., 1996; Meraz et al., 1996).
IFN-b prevents T-cell proliferation and IFN-g secretion
nd may even decrease proliferation of preactivated T
ells (Noronha et al., 1993). HTLV-I mediates T-cell acti-
ation by three separate mechanisms: first, HTLV-I acti-
ates its host T cell (reviewed in (Brady, 1996)); second,
TLV-I-activated T cells may activate resting T cells by
ognate interaction (Kimata et al., 1993; Wucherpfennig
t al., 1992); and third, HTLV-I-infected T cells present
iral peptides in the context of class I, which leads to
D81 T-cell activation (Jacobson et al., 1990). While type
IFNs interfere with the last two mechanisms (D’Onofrio
t al., 1988; Ijichi et al., 1995; Oka et al., 1990), it is not
nown whether they may inhibit the HTLV-I-induced
lonal T-cell activation. To address this question, we
nalyzed HTLV-I-infected T-cell clones generated by sin-
le-cell cloning under limiting dilution conditions from
ndividuals with HAM/TSP.
In productively infected T-cell clones, HTLV-I transcrip-
ion is associated with a state of T-cell activation char-
cterized by incorporation of [3H]thymidine in the ab-
ence of exogenous growth factors after an initial stim-
latory signal (Ho¨llsberg et al., 1992). This phenomenon,
ermed spontaneous clonal proliferation, is not seen in
ninfected T-cell clones and reflects HTLV-I-induced T-
ell activation. Here we demonstrate that HTLV-I-induced
-cell proliferation is resistant to the antiproliferative ac-
ion of IFN-b and, moreover, that HTLV-I-infected T cells
ontinue to constitutively secrete IFN-g in the presence
f high doses of IFN-b. HTLV-I-infected T cells express
ormal levels of IFNAR1 and are able to respond to
FN-b by phosphorylation of STAT1 on Tyr701. Thus,
TLV-I promotes cell cycle progression in G1 by a mech-
nism that overcomes inhibitory signals, thereby circum-
enting an innate immune defense mechanism.
RESULTS
eneration of HTLV-I-infected T-cell clones
Productively infected T-cell clones are characterized
y spontaneous cell cycle progression into S-phase
hile uninfected T-cell clones are dependent on IL-2 for
ell cycle entry (Scholz et al., 1996). This phenomenon,
ermed spontaneous clonal proliferation, indicates that
TLV-I proteins alter normal T-cell activation. To investi-
ate the antiproliferative function of type I IFNs on HTLV-
-induced T-cell activation, T-cell clones were generated
rom the peripheral blood of patients with HAM/TSP by
ingle-cell cloning under limiting dilution conditions
Ho¨llsberg et al., 1992). The T-cell clones Mu.16 (HTLV-I-nfected), Ob1A12.8 (uninfected), and Mu.37 (uninfected)
ave been previously described (Ho¨llsberg et al., 1992;
ucherpfennig et al., 1990). The T-cell clones Ba.24,
a.50, Ba.51, Ba.52, and GK.1E5 were uninfected as de-
ermined by PCR amplification of genomic DNA using
rimers for the LTR region of HTLV-I (data not shown).
he T-cell clones Ba.13, Ki.72, FM.4F5, GK.5G8, GK.5E8,
nd GK.6C2 contained the HTLV-I proviral LTR sequence
n their genomic DNA. In addition, these T-cell clones
xpressed viral mRNA as detected by RT-PCR of tax/rex
RNA and thus were productively infected (data not
hown). As expected, the T-cell clones that expressed pX
RNA displayed spontaneous clonal proliferation, but
emained IL-2-dependent (Table 1).
TLV-I-induced T-cell cycling is resistant to IFN-b-
ediated inhibition
IFN-b inhibited [3H]thymidine incorporation in unin-
ected T-cell clones stimulated by CD3 cross-linking in a
ose-dependent manner (Fig. 1A). In contrast, HTLV-I-
nfected T-cell clones’ incorporation of [3H]thymidine was
ot prevented by 10,000 IU/ml of IFN-b, suggesting that
TLV-I infection induces resistance to the antiprolifera-
ive action of IFN-b. The resistance to IFN-b-mediated
nhibition was demonstrated in four independently gen-
rated HTLV-I-infected T-cell clones from four different
atients. CD3-cross-linking leads to increased [3H]thymi-
ine incorporation in HTLV-I-infected T-cell clones. How-
ver, this superimposed [3H]thymidine incorporation was
nhibited by IFN-b to the level of spontaneous clonal
roliferation (Fig. 1B). Interestingly, in the presence of
igher concentrations of IFN-b the infected T-cell clones
ncreased their incorporation of [3H]thymidine. These
bservations suggest that IFN-b might even be stimula-
ory for the HTLV-I-infected T-cell clones. IFN type I-me-
iated clonal expansion has previously been reported for
urine CD81 T cells (Tough et al., 1996), although the
echanism is unknown.
onstitutive IFN-g secretion from HTLV-I-infected T
ells is not prevented by IFN-b
The HTLV-I encoded protein Tax transactivates the
romoters for a number of cytokine genes (reviewed in
uckle et al. (1996)), one of which is the IFN-g promoter.
his results in the secretion of large quantities of IFN-g
rom HTLV-I-infected T-cell clones, potentially contribut-
ng to the immune activation in infected patients.
hereas IFN-g secretion from CD3-cross-linked, unin-
ected T-cell clones was inhibited by approximately 50%
y 10,000 IU/ml IFN-b, IFN-g secretion from HTLV-I-in-
ected T-cell clones was unaltered or increased (Fig. 2).
his further indicates that HTLV-I-infected T cells escape
he inhibitory function by IFN-b. Moreover, it confirms
hat IFN-b at high concentrations may have a stimulatory
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316 SMITH ET AL.ffect on HTLV-I-infected T cells, since IFN-g production
rom these cells increased at high doses of IFN-b.
TLV-I interferes with membrane distal events in the
ype I IFN signaling pathway
The resistance to IFN-b in HTLV-I-infected T cells
ould be explained by a downregulation of the IFNAR1.
o address this possibility the level of surface expres-
ion of IFNAR1 was measured by indirect immunofluo-
escence analyses (Fig. 3). While the level of expression
f IFNAR1 was low, no difference was detected between
TLV-I-infected and uninfected T-cell clones. Similar
ata were obtained analyzing HTLV-I negative (Jurkat
nd HuT-78), HTLV-I-infected (HuT-102), or Tax-express-
ng (C8166) cell lines (Fig. 3). In addition, Western blot
nalysis of IFNAR1 expression showed comparable ex-
ression in HTLV-I-infected and uninfected T-cell clones
data not shown).
We next analyzed whether binding of IFN-b to its
eceptor induced phosphorylation of STAT1-Tyr701, which
s critical for STAT-1 activity (Shuai et al., 1993). In the
bsence of IFN-b, uninfected T cells had minimally de-
ectable phosphorylation of both STAT1a and STAT1b
Fig. 4). Following IFN-b stimulation, however, STAT1-
yr701 phosphorylation was strongly induced, primarily of
TAT1a. In contrast, low-level basal phosphorylation of
TAT1 was clearly detectable in HTLV-I-infected T cells,
nd while IFN also induced STAT1-Tyr701 phosphoryla-
ion in these cells, it was equally induced in the two
soforms of STAT1.
Autocrine secretion of IFN-a results in sustained JAK
ctivity (Lee et al., 1997), which may lead to constitutive
TAT1 activation. To examine whether HTLV-I-infected T
T
Characterization of T
Cells
HTLV-I
infectiona
HTLV-I
expressionb IL-2-
a.13 1 1
a.24 2 2
a.50 2 2
a.51 2 2
a.52 2 2
M4F5 1 1
i.72 1 1
K6C2 1 1
8166 1 1
uT-102 1 1
urkat 2 2
r.B 2 2
a Presence of LTR by PCR amplification of genomic DNA.
b Presence of pX mRNA by RT-PCR amplification.
c 6standard deviation.
d ND, not determined.ells displayed autocrine secretion of IFN-a, the predom-
nant type I IFN secreted by T cells, supernatants from
nstimulated T-cell clones and cell lines were analyzed
y an IFN-a-specific ELISA. This demonstrated a low-
evel production of IFN-a from HTLV-I-infected and unin-
ected transformed T- or B-cell lines and from two of
hree nontransformed HTLV-I-infected T-cell clones ex-
mined (Table 1). Noticeably, the HTLV-I-infected T-cell
lone with undetectable IFN-a secretion had low-level
pontaneous proliferation. In contrast, IFN-a was unde-
ectable in four uninfected T-cell clones. Incubation of
TLV-I-infected T-cell clones in the presence of a neu-
ralizing antibody to IFN-a did not alter the level of spon-
aneous proliferation (data not shown). Although these
xperiments do not completely exclude a role of auto-
rine production of INF-a in HTLV-I-infected T cells, they
uggest that INF-a is unlikely to account for the altered
TAT1 phosphorylation.
DISCUSSION
An important innate immune defense mechanism is
ediated by type I IFNs, which have both antiviral and
ntiproliferative functions. Type I IFNs may protect unin-
ected T cells against infection by HTLV-I (D’Onofrio et al.,
988) and may inhibit HTLV-I-induced activation of unin-
ected CD41 and CD81 T cells (Ijichi et al., 1995). In
hese instances, IFN mediates its effect on uninfected T
ells, but type I IFNs are also able to prevent virus
roduction and release from an HTLV-I-infected T-cell
ine (Oka et al., 1990). However, the ability of type I IFNs
o alter HTLV-I-induced activation of the host T cell has
ot been examined.
HTLV-I-mediated activation of the host CD41 T cell is
lones and Cell Lines
ent
Spontaneous [3H]TdR
incorporation (cpm)
Spontaneous IFN-a
secretion (pg/ml)
9,287 6 356c NDd
139 6 65 ,20
182 6 61 ,20
210 6 53 ,20
176 6 64 ,20
27,821 6 2,316 32 6 5c
2,570 6 282 ,20
9,076 6 627 31 6 0
139,306 6 26,441 42 6 10
175,051 6 4,001 24 6 1
548,795 6 28,318 43 6 16
177,242 6 3,329 24 6 0ABLE 1
-Cell C
depend
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317HTLV-I-INFECTED T CELLS EVADE ACTION OF IFN-bikely a contributing factor to HTLV-I pathogenesis (Ho¨lls-
erg, 1997). For example, activation of the infected T cell
ay predispose to leukemic changes. In addition, the
ctivated and infected CD41 T cells may cross the blood-
brain barrier and gain access to the central nervous
ystem, which may be important for the pathogenesis of
AM/TSP (Ho¨llsberg, 1997). In the present paper, we
ave demonstrated that whereas IFN-b inhibits T-cell
ctivation mediated by CD3-cross-linking, it is unable to
revent HTLV-I-induced T-cell activation or IFN-g secre-
ion. The nuclear events connected with the antiprolif-
rative action of type I IFNs on T cells are unclear. In its
ypophosphorylated form, the retinoblastoma protein
pRb) is a negative regulator of cell cycle progression,
nd stimuli that induce T-cell proliferation activate cyclin-
ependent kinases (CDKs), which subsequently phos-
FIG. 1. HTLV-I-induced spontaneous clonal proliferation is resistant
o the inhibition by IFN-b. (A) T cells from HTLV-I-infected and unin-
ected clones were incubated at 105 cells per well in the absence of
xogenous growth factors. Uninfected T cells do not spontaneously
roliferate and were incubated in the presence or in the absence of
late-bound anti-CD3 mAb. Incorporation of [3H]thymidine was mea-
ured during the last 16 h of a 66-h incubation. A representative
xperiment of four independent experiments is shown. (B) Superim-
osed activation of HTLV-I-infected T-cell clones is inhibited by IFN-b.horylate pRb. It has been suggested that STAT1 is an
ssential mediator of the antiproliferative action of type I
FNs in part through induction of the CDK inhibitor
21WAF1/CIP1 (Chin et al., 1996). Two families of CDK
nhibitors have been described and p21WAF1/CIP1, to-
ether with p27KIP1 and p57KIP2, belongs to a family
hat may inhibit all CDKs (Sherr, 1996). If induction of
21WAF1/CIP1 is the major mechanism by which IFN-b
xerts its antiproliferative action in T cells, it suggests
hat HTLV-I-infected T cells are insensitive to p21WAF1/CIP1-
ediated inhibition. This possibility is attractive, since
he promoter for p21WAF1/CIP1 is already upregulated by
ax without inhibition of cell cycling (Akagi et al., 1996;
ereseto et al., 1996).
Thus we hypothesize that the lack of inhibition by
FN-b in HTLV-I-infected T cells is due to virally mediated
orced cell cycle progression. We have previously dem-
nstrated that transforming growth factor (TGF-b) fails to
revent cell cycle progression in HTLV-I-infected T cells
Ho¨llsberg et al., 1994). TGF-b interferes with the assem-
ly of active cyclin/CDK complexes during G1 of the cell
ycle, thereby preventing pRb phosphorylation and G1- to
-phase transition (Sherr, 1996). HTLV-I-infected T cells
ave constitutive phosphorylation of pRb, but unexpect-
dly this is not prevented in the presence of TGF-b.
ndeed, Tax eliminates the inhibitory function of p16INK4a
Low et al., 1997; Suzuki et al., 1996), a member of the
ther family of CDK inhibitors. This results in activation of
DK4 and CDK6 and resultant phosphorylation and in-
ctivation of the suppressor function of pRb (Low et al.,
997; Schmitt et al., 1998; Suzuki et al., 1996). It is there-
ore possible that HTLV-I infection results in pRb phos-
horylation in a manner that is not prevented by either
ype I IFNs or TGF-b.
Recent data have suggested that in transformed T-cell
ines, the assembly of a signaling complex consisting of
FIG. 2. Constitutive secretion of IFN-g by HTLV-I-infected T-cell
lones in the presence of IFN-b. Supernatant was collected 48 h after
nset of culture. The uninfected T-cell clone was stimulated with
late-bound CD3 antibodies.
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318 SMITH ET AL.D45, Lck, and ZAP-70 at the IFNAR is necessary for the
ntiproliferative action of IFN-a (Petrocoin et al., 1997).
ince Lck is frequently downregulated in HTLV-I-trans-
ormed T-cell lines (Koga et al., 1989), this may potentially
xplain an impaired antiproliferative action of IFN-b on
TLV-I-transformed T-cell lines. However, it is unlikely
hat this would account for the altered response of HTLV-
-infected T-cell clones to IFN-b, since three observa-
ions suggest that IFN-b does transmit a signal in these
ells: first, IFN-b induces STAT1 phosphorylation on
yr701; second, the HTLV-I-infected T-cell clones respond
n some cases with an increased rather than a de-
reased response to high doses of IFN-b; and third, the
uperimposed stimulation by CD3-cross-linking is inhib-
ted by IFN-b. Moreover, downregulation of Lck is ob-
FIG. 3. Expression of IFNAR1 by HTLV-I-infected T cells. Surface expr
easured by flow cytometry.
FIG. 4. STAT1 phosphorylation on Tyr701 by IFN-b treatment in HTLV-
-infected and uninfected T-cell clones. HTLV-I-infected and uninfected
-cell clones were incubated for 0, 1, and 10 min in the presence IFN-b.
hole T-cell lysate was examined by Western blot analysis for the
resence of Tyr701 phosphorylated STAT1. A representative of two
xperiments is shown.erved in HTLV-I-transformed T cells and not in nontrans-
ormed T-cell clones (Koga et al., 1989).
The HTLV-I-infected T-cell clones displayed a low-level
asal Tyr701 phosphorylation of STAT1. Whereas the au-
ocrine production of IFN-a was barely detectable, the
roduction of IFN-g was substantial. Thus, constitutive
hosphorylation of STAT1 is more likely to result from
FN-g than from autocrine IFN-a production. Despite the
igh level of IFN-g the constitutive phosphorylation of
TAT1 was not striking. Although the reason for this is
ot clear, it may be associated with downregulation of
he IFN-g receptor and the transient phosphorylation of
TAT1 by IFN-g. Preliminary analyses have failed to de-
ect Tyr701-phosphorylated STAT1 in the HTLV-I-infected
-cell line HuT-102 (P.H. and D.A.F., unpublished obser-
ations), which produces little, if any, IFN-g or IFN-a.
The HTLV-I-infected T-cell clones differed from unin-
ected T-cell clones in their relative increase in STAT1b
yr701 phosphorylation when compared with STAT1a.
hereas both STAT1a and STAT1b become tyrosine
hosphorylated on Tyr701, translocate to the nucleus, and
ind DNA, only STAT1a is associated with transcriptional
ctivation (Shuai et al., 1993). This indicates that STAT1b
ight counteract transcriptional activation (Shuai et al.,
993) and suggests that the relative increase in phos-
horylation of STAT1b when compared with STAT1a in
TLV-I-infected T cells may potentially contribute to the
ack of antiproliferative effect of IFN-b.
Clinically, type I IFN is used to treat HTLV-I-associated
iseases. While IFN-a alone is inefficient in treating
of IFNAR1 was analyzed by indirect immunofluorescence staining andession
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319HTLV-I-INFECTED T CELLS EVADE ACTION OF IFN-bTLV-I-induced leukemia–lymphoma, it may be benefi-
ial in combination with zidovudine (Gill et al., 1995;
ermine et al., 1995). IFN-a alone may have beneficial
ffects in some patients with HAM/TSP (Ijichi et al.,
995). However, lack of inhibition of HTLV-I-induced ac-
ivation of the host T cell by type I IFN may be important,
s infected T cells may cross the blood–brain barrier by
irtue of their activated state and interact with resting T
ells in the CNS that are not exposed to therapeutically
dministered type I IFN.
MATERIALS AND METHODS
ells and reagents
T-cell clones from patients with HAM/TSP were gen-
rated by single-cell cloning under limiting dilution con-
itions (Ho¨llsberg et al., 1992) using phytohemagglutinin
PHA-P, Murex Diagnostics, Norcross, GA). Cells were
ultured in RPMI 1640 supplemented with 100 u/ml pen-
cillin, 100 mg/ml streptomycin, 10 mM HEPES, 4 mM
-glutamine, 10% human serum (all from Biowhittaker,
alkersville, MD), and 10% Human T-Stim (Collaborative
iomedicine Products, Bedford, MA). Proviral integration
nd viral expression were determined by PCR amplifica-
ion of a region in the long terminal repeat (LTR) of HTLV-I
nd by RT-PCR of pX mRNA, respectively. The primers for
he LTR region and for the pX region have been de-
cribed previously (Greenberg et al., 1989; Scholz et al.,
996). The T-cell lines C8166 (expressing Tax but not viral
articles), HuT-102 (HTLV-I-infected), HuT-78 (HTLV-I
egative), and Jurkat (HTLV-I negative) were from ATTC
Rockville, MD). Ar.B is an EBV-transformed B-cell line
Ho¨llsberg et al., 1995). The rabbit polyclonal antibody to
yr701-phosphorylated murine STAT1 was raised against
he following specific peptide sequence, where the as-
erisk denotes the phosphorylated tyrosine residue:
DPKRTGY*IKTE (Frank et al., 1995). An N-terminal Cys
as used to couple the peptides to BSA for the immuni-
ation. This antibody recognizes both STAT1a and
TAT1b and can cross-react with Tyr-phosphorylated
TAT5, which runs as a 95-kDa protein by SDS–PAGE
nd therefore is easily distinguished from the phosphor-
lated STAT1a and STAT1b. The anti-IFNAR1 antibodies
A12 (Goldman et al., 1998) and GB8 were a gift from
iogen Inc. (Cambridge, MA). GB8 recognizes an epitope
n the extracellular region of IFNAR1 between amino
cids 278 and 293 (Ling et al., 1995). The neutralizing
ntibody to IFN-a was from BioSource International
Camarillo, CA).
3H]Thymidine incorporation assay
At day 8–10 after restimulation with 2 mg/ml PHA
nd irradiated feeder cells, 105 T cells were plated per
ell in a 96-well flat-bottom plate, which had beenrecoated with either anti-CD3 (ATCC, OKT3 cell line,
onoclonal IgG2a) or control mouse IgG2a (Pharmin-
en, San Diego, CA). Increasing doses of IFN-b1b
Berlex Laboratories, Richmond, CA) were added at
he onset of culture to triplicate wells. Each well was
ulsed with 1 mCi of [3H]thymidine for 18 h and har-
ested by an automated cell harvester (Beta plate
295-004, Wallac, Gaithersburg, MD). The uptake of
3H]thymidine was measured in a beta scintillation
ounter (Beta plate 1205, Wallac). Results are pre-
ented as means of triplicate cultures 6 SE.
LISA
Supernatants for IFN-g or IFN-a measurements were
aken 40 h after onset of culture. IFN-g was measured
sing a sandwich immunoassay as previously described
Scholz et al., 1996). IFN-a was measured using the
ytoscreen immunoassay kit for human IFN-a from Bio-
ource International. The antibodies in this assay do not
ross-react with IFN-b or IFN-g according to the manu-
acturer. The sensitivity of the assay was ,20 pg/ml.
low cytometry analysis
Cells were washed twice in PBS and 106 cells per
ample were incubated for 30 min at 4°C with 5 mg/ml
B8 anti-IFNAR1 mAb (a gift from Biogen, Cambridge,
A) or a control mouse IgG1 (Pharmingen). Unbound
rimary antibody was removed by washing the samples
hree times in complete medium with 10% fetal bovine
erum. Samples were then incubated for 30 min at 4°C
ith FITC-conjugated goat anti-mouse IgG1 (Coulter, Hi-
leah, FL), washed twice, and fixed in 1% paraformalde-
yde in PBS. Flow cytometric analyses of 104 cells per
ample were performed on a FACScan flow cytometer
Beckton Dickinson Immunocytometry Systems, San
ose, CA) using CELLQuest software (version 2.1; Beck-
on Dickinson).
estern blot analysis
HTLV-I-infected and uninfected T cells were either
nstimulated or stimulated for 1 or 10 min with 104 IU/ml
f IFN-b1. Cells were lysed for 20 min on ice in 1% Triton
ysis buffer (containing 20 mM Tris–HCl, pH 8.0, 150 mM
aCl, 1 mM phenylmethylsulfonylfluoride, and 1 mM
a3VO4). Twenty-five micrograms of protein, as deter-
ined by the method of Bradford, was loaded onto an 8%
DS–polyacrylamide gel. The resolved protein was sub-
equently blotted to nitrocellulose (Amersham, Arlington
eights, IL), preblocked for 1 h in a buffer consisting of
% nonfat dry milk and 0.1% Tween 20 (Sigma) in PBS,
nd incubated overnight at 4°C on a shaking platform
ith primary antibody at 1:1000 dilution in PBS with 0.1%
ween 20. The nitrocellulose blot was washed three
imes in PBS with 0.1% Tween 20 and incubated for 1 h
w
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320 SMITH ET AL.ith a 1:1000 dilution of donkey anti-rabbit horseradish
eroxidase-conjugated antibody (Amersham). The blot
as washed 5 times in PBS with 0.1% Tween 20 and
eveloped using enhanced chemiluminescence (ECL,
mersham).
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